Search research articles
Contact Us
Filters
Showing results (11-20 of 67) with videos related to
Page
of 7
Sort By:
Pharmacoeconomics
|
October 28, 1999
Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma
C A Uyl-de Groot, G J Ossenkoppele, I Buijt, et al.
Anti-Cancer Drugs
|
January 16, 1999
Costs of intensive treatment and follow-up of patients with multiple myeloma
I Buijt, G J Ossenkoppele, C A Uyl-de Groot, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
August 4, 2020
The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
N Van der Linden, S Van Olst, S Nekeman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2007
Stem cell transplantation in Europe: trends and prospects
S S Tan, C A Uyl-de Groot, P C Huijgens, et al.
Medical Oncology (Northwood, London, England)
|
September 1, 1996
Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters
L S Hofstra, E G de Vries, C A Uyl-de Groot, et al.
Bone Marrow Transplantation
|
September 1, 1995
Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL)
C A Uyl-de Groot, A Hagenbeek, L F Verdonck, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
March 27, 2004
[The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation]
M T Groot, M van Agthoven, B Löwenberg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2001
Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial
M van Agthoven, E Vellenga, W E Fibbe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1994
The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma
C A Uyl-de Groot, G J Ossenkoppele, A A van Riet, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
February 3, 2004
[Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice]
M van Agthoven, S Wittebol, L M Budel, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 67) with videos related to
Sort By:
Page
of 7
Pharmacoeconomics
|
October 28, 1999
Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma
C A Uyl-de Groot, G J Ossenkoppele, I Buijt, et al.
Anti-Cancer Drugs
|
January 16, 1999
Costs of intensive treatment and follow-up of patients with multiple myeloma
I Buijt, G J Ossenkoppele, C A Uyl-de Groot, et al.
Diabetic Medicine : a Journal of the British Diabetic Association
|
August 4, 2020
The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
N Van der Linden, S Van Olst, S Nekeman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2007
Stem cell transplantation in Europe: trends and prospects
S S Tan, C A Uyl-de Groot, P C Huijgens, et al.
Medical Oncology (Northwood, London, England)
|
September 1, 1996
Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters
L S Hofstra, E G de Vries, C A Uyl-de Groot, et al.
Bone Marrow Transplantation
|
September 1, 1995
Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL)
C A Uyl-de Groot, A Hagenbeek, L F Verdonck, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
March 27, 2004
[The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation]
M T Groot, M van Agthoven, B Löwenberg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2001
Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial
M van Agthoven, E Vellenga, W E Fibbe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1994
The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma
C A Uyl-de Groot, G J Ossenkoppele, A A van Riet, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
February 3, 2004
[Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice]
M van Agthoven, S Wittebol, L M Budel, et al.
Page
of 7